ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Allergan will reduce its workforce by 1,500, or about 13%, this year as part of a restructuring program it hopes will deliver $475 million in pretax savings in 2015. About 650 of the jobs are at the firm’s R&D facility in Irvine, Calif. Allergan, manufacturer of the cosmetic enhancer and drug Botox, made the announcement while reporting a 15.9% increase in second-quarter sales compared with last year to $1.8 billion. Meanwhile, the company continues to fend off a hostile acquisition bid by Valeant Pharmaceuticals, calling Valeant’s latest offer of $53 billion in cash and stock “grossly inadequate.”
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter